Abstract | OBJECTIVE: METHODS: RESULTS: Relative to placebo, both CEE and CEE+MPA caused a significant reduction in plasma RLP-C concentrations and a significant increase in alpha1 and alpha2 HDL subpopulations. However, in the HT-treated subjects, faster progression of coronary atherosclerosis was observed in women who experienced the greatest reductions in RLP-C and in prebeta1 HDL subpopulations. CONCLUSIONS: Our data suggest that individual variability in RLP-C and HDL subpopulation response to HT is a predictor of CHD progression. Lipoprotein response to HT may be an indirect marker of susceptibility to other harmful effect of HT in postmenopausal women with established CHD or an indication of formation of dysfunctional lipoproteins.
|
Authors | Stefania Lamon-Fava, David M Herrington, David M Reboussin, Michelle Sherman, Katalin Horvath, Ernst J Schaefer, Bela F Asztalos |
Journal | Atherosclerosis
(Atherosclerosis)
Vol. 205
Issue 1
Pg. 325-30
(Jul 2009)
ISSN: 1879-1484 [Electronic] Ireland |
PMID | 19155011
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Estrogens, Conjugated (USP)
- Hormones
- Lipoproteins, HDL
- Placebos
- Cholesterol
|
Topics |
- Aged
- Cholesterol
(metabolism)
- Coronary Angiography
(methods)
- Coronary Disease
(blood)
- Disease Progression
- Estrogen Replacement Therapy
(methods)
- Estrogens, Conjugated (USP)
(therapeutic use)
- Female
- Hormones
(therapeutic use)
- Humans
- Lipoproteins, HDL
(biosynthesis)
- Middle Aged
- Placebos
- Postmenopause
|